Should Response-Adapted Therapy Now Be the Standard of Care for Advanced Hodgkin’s Lymphoma?

অনুযায়ী Johnson, Peter, Longley, Jemma
প্রকাশিত Curr Treat Options Oncol (2017)

Options for first line therapy of Hodgkin lymphoma

অনুযায়ী Longley, Jemma, Johnson, Peter W.M.
প্রকাশিত Hematol Oncol (2019)

Epigenetics of Indolent Lymphoma and How It Drives Novel Therapeutic Approaches—Focus on EZH2-Targeted Drugs

অনুযায়ী Longley, Jemma, Johnson, Peter W. M.
প্রকাশিত Curr Oncol Rep (2021)

Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors

অনুযায়ী Yap, Timothy A., Winter, Jane N., Giulino-Roth, Lisa, Longley, Jemma, Lopez, Juanita, Michot, Jean-Marie, Leonard, John P., Ribrag, Vincent, McCabe, Michael T., Creasy, Caretha L., Stern, Melissa, Pene Dumitrescu, Teodora, Wang, Xiaowei, Frey, Steve, Carver, Jennifer, Horner, Thierry, Oh, Choon, Khaled, Ahmed, Dhar, Arindam, Johnson, Peter W.M.
প্রকাশিত Clin Cancer Res (2019)